Published in Paediatr Drugs on May 27, 2017
Extrathymically generated regulatory T cells control mucosal TH2 inflammation. Nature (2012) 4.33
Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition. Nat Med (2014) 3.54
Genome-wide association study in alopecia areata implicates both innate and adaptive immunity. Nature (2010) 2.85
Alopecia areata. N Engl J Med (2012) 2.56
Alopecia areata update: part I. Clinical picture, histopathology, and pathogenesis. J Am Acad Dermatol (2010) 2.48
Incidence of alopecia areata in Olmsted County, Minnesota, 1975 through 1989. Mayo Clin Proc (1995) 1.99
History of atopy or autoimmunity increases risk of alopecia areata. J Am Acad Dermatol (2009) 1.96
A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis. Br J Dermatol (2013) 1.83
Placebo-controlled oral pulse prednisolone therapy in alopecia areata. J Am Acad Dermatol (2005) 1.75
Killing two birds with one stone: oral tofacitinib reverses alopecia universalis in a patient with plaque psoriasis. J Invest Dermatol (2014) 1.73
Alopecia areata: a long term follow-up study of 191 patients. J Am Acad Dermatol (2006) 1.56
Interventions for alopecia areata. Cochrane Database Syst Rev (2008) 1.55
Double-blind, placebo-controlled, dose-escalation study to evaluate the pharmacologic effect of CP-690,550 in patients with psoriasis. J Invest Dermatol (2009) 1.54
Alopecia areata update: part II. Treatment. J Am Acad Dermatol (2010) 1.44
Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study. Br J Dermatol (2012) 1.42
Genome-wide meta-analysis in alopecia areata resolves HLA associations and reveals two new susceptibility loci. Nat Commun (2015) 1.32
Profile of 513 patients with alopecia areata: associations of disease subtypes with atopy, autoimmune disease and positive family history. J Eur Acad Dermatol Venereol (2006) 1.20
Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib. EBioMedicine (2015) 1.15
Intralesional treatment of alopecia areata with triamcinolone acetonide by jet injector. Br J Dermatol (1973) 1.12
Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, improves patient-reported outcomes in a phase 2b, randomized, double-blind, placebo-controlled study in patients with moderate-to-severe psoriasis. J Eur Acad Dermatol Venereol (2013) 1.09
A comparison of intra-lesional triamcinolone hexacetonide and triamcinolone acetonide in alopecia areata. Br J Dermatol (1971) 1.07
Intravenous corticosteroids: adverse reactions are more variable than expected in children. J Rheumatol (1998) 1.05
Clobetasol propionate 0.05% under occlusion in the treatment of alopecia totalis/universalis. J Am Acad Dermatol (2003) 1.04
Phase I/II randomized bilateral half-head comparison of topical bexarotene 1% gel for alopecia areata. J Am Acad Dermatol (2009) 1.03
Alopecia areata in children: a clinical profile. Pediatr Dermatol (2002) 1.02
Double-blind, placebo-controlled evaluation of topical minoxidil in extensive alopecia areata. J Am Acad Dermatol (1987) 1.01
Alopecia areata treated with tropical minoxidil. J R Soc Med (1982) 1.00
Systemic steroids with or without 2% topical minoxidil in the treatment of alopecia areata. Arch Dermatol (1992) 0.97
Topical use of minoxidil in children and systemic side effects. Dermatology (2007) 0.95
Juvenile versus maturity-onset alopecia areata--a comparative retrospective clinical study. Clin Exp Dermatol (1989) 0.94
Minoxidil induced hypertrichosis in a 2 year-old child. F1000Res (2013) 0.93
Topical minoxidil in the treatment of alopecia areata. Br Med J (Clin Res Ed) (1983) 0.93
JAK inhibitors: treatment efficacy and safety profile in patients with psoriasis. J Immunol Res (2014) 0.90
Treatment of severe alopecia areata with intralesional steroid injections. J Drugs Dermatol (2009) 0.90
The epidemiology of childhood alopecia areata in China: a study of 226 patients. Pediatr Dermatol (2006) 0.89
Efficacy and safety of diphenylcyclopropenone alone or in combination with anthralin in the treatment of chronic extensive alopecia areata: a retrospective case series. J Am Acad Dermatol (2015) 0.88
An insight into JAK-STAT signalling in dermatology. Clin Exp Dermatol (2014) 0.88
308-nm excimer laser for the treatment of alopecia areata in children. Pediatr Dermatol (2009) 0.86
Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients. J Am Acad Dermatol (2016) 0.85
Efficacy and tolerability of methotrexate in severe childhood alopecia areata. Br J Dermatol (2011) 0.85
Methotrexate in Severe Childhood Alopecia Areata: Long-term Follow-up. Acta Derm Venereol (2016) 0.84
Long-term results of topical immunotherapy in children with alopecia totalis or alopecia universalis. J Am Acad Dermatol (1996) 0.83
A clinical study of childhood alopecia areata in Singapore. Pediatr Dermatol (2002) 0.83
Efficacy and Safety of Methotrexate Combined with Low- to Moderate-Dose Corticosteroids for Severe Alopecia Areata. Dermatology (2016) 0.83
Topical tacrolimus in alopecia areata. J Am Acad Dermatol (2005) 0.83
Topical Ruxolitinib for the Treatment of Alopecia Universalis. JAMA Dermatol (2016) 0.83
Pulse corticosteroid therapy for alopecia areata in children: a retrospective study. Dermatology (2013) 0.82
Interest of high-dose pulse corticosteroid therapy combined with methotrexate for severe alopecia areata: a retrospective case series. Dermatology (2012) 0.81
Efficacy and safety of methotrexate in alopecia areata. An Bras Dermatol (2014) 0.81
Transient Efficacy of Tofacitinib in Alopecia Areata Universalis. Case Rep Dermatol (2016) 0.81
The role of hair follicle immune privilege collapse in alopecia areata: status and perspectives. J Investig Dermatol Symp Proc (2013) 0.81
Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata. JCI Insight (2016) 0.80
Tofacitinib for the treatment of alopecia areata and variants in adolescents. J Am Acad Dermatol (2016) 0.79
Allergy to dust mites may contribute to early onset and severity of alopecia areata. Clin Exp Dermatol (2014) 0.78
The safety and efficacy of diphencyprone for the treatment of alopecia areata in children. Arch Dermatol (2012) 0.77
Psychiatric symptomatology and health-related quality of life in children and adolescents with alopecia areata. J Eur Acad Dermatol Venereol (2013) 0.76
Bilateral Half-Head Comparison of 1% Anthralin Ointment in Children with Alopecia Areata. Pediatr Dermatol (2017) 0.76
Treatment of Alopecia Areata in the United States: A Retrospective Cross-Sectional Study. J Drugs Dermatol (2015) 0.76
Treatment of an alopecia areata patient with tofacitinib results in regrowth of hair and changes in serum and skin biomarkers. Exp Dermatol (2016) 0.76
Treatment of widespread alopecia areata in young patients with monthly oral corticosteroid pulse. Pediatr Dermatol (1998) 0.76
Cytokines and signal transduction pathways mediated by anthralin in alopecia areata-affected Dundee experimental balding rats. J Investig Dermatol Symp Proc (2003) 0.76
Poor long term outcome of severe alopecia areata in children treated with high dose pulse corticosteroid therapy. Br J Dermatol (2008) 0.76
Comparative assessment of topical steroids, topical tretenoin (0.05%) and dithranol paste in alopecia areata. Indian J Dermatol (2010) 0.76
Experience with oral tofacitinib in 8 adolescent patients with alopecia universalis. J Am Acad Dermatol (2017) 0.76
High Relapse Rates Despite Early Intervention with Intravenous Methylprednisolone Pulse Therapy for Severe Childhood Alopecia Areata. Pediatr Dermatol (2015) 0.76
Combined oral pulse and topical corticosteroid therapy for severe alopecia areata in children: a long-term follow-up study. Dermatol Ther (2015) 0.75
Clobetasol propionate, 0.05%, vs hydrocortisone, 1%, for alopecia areata in children: a randomized clinical trial. JAMA Dermatol (2014) 0.75
Skin disease and thyroid autoimmunity in atopic South Italian children. World J Clin Pediatr (2016) 0.75